THE EMERGING ROLE OF CARDIAC BIOMARKERS IN RISK STRATIFICATION AND MANAGEMENT OF CARDIOVASCULAR DISEASES

Abstract

Cardiac biomarkers have emerged as essential tools in risk stratification and management of cardiovascular diseases. This systematic review investigated the role of these biomarkers in clinical practice by examining studies published in the last 10 years. 25 relevant studies were identified, including randomized controlled trials, prospective cohort studies and systematic reviews. Troponin, B-type natriuretic peptide (BNP) and C-reactive protein (CRP) were the most studied biomarkers, demonstrating significant associations with adverse cardiovascular outcomes, such as myocardial infarction and heart failure. Furthermore, emerging biomarkers such as miRNA and galectin-3 have shown promise in assessing cardiovascular risk. However, challenges remain regarding the standardization of laboratory assays and the interpretation of results. Future research should focus on validating emerging biomarkers and developing strategies for their implementation into clinical practice. These advances have the potential to improve accuracy in identifying at-risk patients and optimize therapeutic management of cardiovascular disease.